Addition of Venetoclax at Time of Progression in Ibrutinib‐treated Patients With Chronic Lymphocytic Leukemia: Combination Therapy to Prevent Ibrutinib Flare

American Journal of Hematology - United States
doi 10.1002/ajh.25690
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Anticoagulant Therapy in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Comorbidities Predict Inferior Outcomes in Chronic Lymphocytic Leukemia Treated With Ibrutinib

Cancer
Cancer ResearchOncology
2018English

Beyond Ibrutinib Resistance in Chronic Lymphocytic Leukemia

Cancer therapy & Oncology International Journal
2017English

Amebic Encephalitis in a Patient With Chronic Lymphocytic Leukemia on Ibrutinib Therapy

Case Reports in Hematology
2018English

Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia With Ibrutinib

Clinical Cancer Research
Cancer ResearchOncology
2016English

Ibrutinib Therapy Releases Leukemic Surface IgM From Antigen Drive in Chronic Lymphocytic Leukemia Patients.

Clinical Cancer Research
Cancer ResearchOncology
2018English

Experience With Ibrutinib in Patients With Refractory and Recurrent B-Cell Chronic Lymphocytic Leukemia

Medical Council
2017English

Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Comparison of Innate Immunity Changes Following Ibrutinib and Venetoclax Treatment of Relapsed Chronic Lymphocytic Leukaemia

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy